Viking Therapeutics (VKTX) stock ripped higher on Sept. 22 after the biotech firm disclosed positive top-line results from its Phase 2 trial involving its lead dual GLP-1/GIP agonist — VK2735. The study showed up to 22% placebo-adjusted weight loss at 33 weeks and confirmed the viability of flexible monthly and biweekly dosing.
Following today’s surge, Viking Therapeutics stock is up roughly 8% versus the start of this year, but down the same from its July high.